Latest US company accused of price gouging, after 2,469% increase
pharmafile | December 12, 2017 | News story | Manufacturing and Production, Sales and Marketing |Â Â Avondale Pharmaceutical, Niacor, biotech, drugs, pharma, pharmaceuticalÂ
It seems that no matter how much bad press comes their way, certain pharmaceutical companies are more than happy to take a little heat to make quick money.
The latest to come to light is Avondale Pharmaceutical and the huge prices increases on two drugs it bought before subsequently hiking the price.
The two medicines are Niacor and SSKI, with price increases by 809% and 2,469%, respectively. There was no attempt by Avondale to try to hide the increases by raising the prices gradually, the route taken by Mylan during the EpiPen scandal that rocked the company towards the latter end of last year.
Instead, last month, shortly after acquiring the two drugs from Upsher Smith, a division of Sawai Pharmaceutical, the prices of both products shot up: for Niacor, this meant an increase from $32.46 to $295 and for SSKI, from $11.48 to $295.
The two products are the only medicines that Avondale has in its portfolio and the full details have not been released of the deal struck between the company and Upsher Smith.
Niacor is an FDA approved treatment for high cholesterol and is a type of vitamin B3, coming in 100 tablets packages. Despite there being many generic alternatives on the market, that can cost as little as $10, doctors sometimes prefer to prescribe FDA approved medicines.
The product was prescribed close to 19,000 times last year alone – if the price and prescription levels were to stay the same, that would mean total expenditure on Niacor would rise from $616,740 in 2016 to $5.6 million in 2018.
This might be possible due to the fact that many physicians will be unaware that the price of the product has increased so dramatically – an inefficiency that could add $5 million onto the annual bill for the product.
As reported by the Financial Times, the business dealings of Avondale remain shady – with a registered address but no means of contacting the company over the price increases.
Mark Pugh, appears to be CEO of Avondale but is also associated with Acrogen Pharmaceuticals whilst his LinkedIn states that he is currently CEO of Acella Pharmaceuticals.
Ben Hargreaves
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …
